Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Jun 21;17(1):439.
doi: 10.1186/s12885-017-3416-0.

Cerebellar mutism syndrome in children with brain tumours of the posterior fossa

Morten Wibroe  1   2 , Johan Cappelen  3 , Charlotte Castor  4 , Niels Clausen  5 , Pernilla Grillner  6 , Thora Gudrunardottir  7   8 , Ramneek Gupta  9 , Bengt Gustavsson  10 , Mats Heyman  6 , Stefan Holm  6 , Atte Karppinen  11 , Camilla Klausen  12 , Tuula Lönnqvist  13 , René Mathiasen  2 , Pelle Nilsson  14 , Karsten Nysom  2 , Karin Persson  15 , Olof Rask  4 , Kjeld Schmiegelow  2   16   17 , Astrid Sehested  2 , Harald Thomassen  18 , Ingrid Tonning-Olsson  4 , Barbara Zetterqvist  19 , Marianne Juhler  20   21
Affiliations
Clinical Trial

Cerebellar mutism syndrome in children with brain tumours of the posterior fossa

Morten Wibroe et al. BMC Cancer. .

Abstract

Background: Central nervous system tumours constitute 25% of all childhood cancers; more than half are located in the posterior fossa and surgery is usually part of therapy. One of the most disabling late effects of posterior fossa tumour surgery is the cerebellar mutism syndrome (CMS) which has been reported in up to 39% of the patients but the exact incidence is uncertain since milder cases may be unrecognized. Recovery is usually incomplete. Reported risk factors are tumour type, midline location and brainstem involvement, but the exact aetiology, surgical and other risk factors, the clinical course and strategies for prevention and treatment are yet to be determined.

Methods: This observational, prospective, multicentre study will include 500 children with posterior fossa tumours. It opened late 2014 with participation from 20 Nordic and Baltic centres. From 2016, five British centres and four Dutch centres will join with a total annual accrual of 130 patients. Three other major European centres are invited to join from 2016/17. Follow-up will run for 12 months after inclusion of the last patient. All patients are treated according to local practice. Clinical data are collected through standardized online registration at pre-determined time points pre- and postoperatively. Neurological status and speech functions are examined pre-operatively and postoperatively at 1-4 weeks, 2 and 12 months. Pre- and postoperative speech samples are recorded and analysed. Imaging will be reviewed centrally. Pathology is classified according to the 2007 WHO system. Germline DNA will be collected from all patients for associations between CMS characteristics and host genome variants including pathway profiles.

Discussion: Through prospective and detailed collection of information on 1) differences in incidence and clinical course of CMS for different patient and tumour characteristics, 2) standardized surgical data and their association with CMS, 3) diversities and results of other therapeutic interventions, and 4) the role of host genome variants, we aim to achieve a better understanding of risk factors for and the clinical course of CMS - with the ultimate goal of defining strategies for prevention and treatment of this severely disabling condition.

Trial registration: Clinicaltrials.gov : NCT02300766 , date of registration: November 21, 2014.

Keywords: Brain tumour; CMS; Cancer; Cerebellar mutism; Cerebellum; Children; Genetics; Neurosurgery; Paediatric; Posterior fossa syndrome.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The follow up process in case of repeated surgeries
See this image and copyright information in PMC

References

    1. Rickert CH, Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst. 2001;17(9):503–511. doi: 10.1007/s003810100496. - DOI - PubMed
    1. Sonderkaer S, Schmiegelow M, Carstensen H, Nielsen LB, Muller J, Schmiegelow K. Long-term neurological outcome of childhood brain tumors treated by surgery only. J Clin Oncol. 2003;21(7):1347–1351. doi: 10.1200/JCO.2003.08.009. - DOI - PubMed
    1. Radcliffe J, Packer RJ, Atkins TE, Bunin GR, Schut L, Goldwein JW, Sutton LN. Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. Ann Neurol. 1992;32(4):551–554. doi: 10.1002/ana.410320411. - DOI - PubMed
    1. Ellenberg L, McComb JG, Siegel SE, Stowe S. Factors affecting intellectual outcome in pediatric brain tumor patients. Neurosurgery. 1987;21(5):638–644. doi: 10.1227/00006123-198711000-00006. - DOI - PubMed
    1. Livesey EA, Hindmarsh PC, Brook CG, Whitton AC, Bloom HJ, Tobias JS, Godlee JN, Britton J. Endocrine disorders following treatment of childhood brain tumours. Br J Cancer. 1990;61(4):622–625. doi: 10.1038/bjc.1990.138. - DOI - PMC - PubMed

MeSH terms

Associated data